Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
Work
Year: 2012
Type: article
Abstract: Resistance to therapy with BRAF kinase inhibitors is associated with reactivation of the mitogen-activated protein kinase (MAPK) pathway. To address this problem, we conducted a phase 1 and 2 trial of... more
Source: New England Journal of Medicine
Institutions Massachusetts General Hospital, Tennessee Oncology, Sarah Cannon, University of California, San Francisco, University of Colorado Denver +13 more
Cites: 27
Cited by: 2,693
Related to: 10
FWCI: 134.7
Citation percentile (by year/subfield): 100
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Sustainable Development Goal Good health and well-being
Open Access status: bronze